3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1/2
1
Status
Completed
6
Recruiting
3
Active not recruiting
2
Unknown
1
Not yet recruiting
1
Enrolling by invitation
1
Sponsor Class
INDUSTRY
2
OTHER
1
Study Type
Interventional
3
Sponsor
Cancer Type
Breast
2
Tumor-Agnostic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Conditions
Breast Neoplasms
45
Endometrial Neoplasms
10
Triple Negative Breast Neoplasms
4
Ovarian Neoplasms
3
Neoplasms
3
Neoplasm Metastasis
3
Fallopian Tube Neoplasms
3
Progesterone Resistance
2
HR+/HER2- Breast Cancer
2
HR Positive HER2 Negative Advanced Breast Cancer
2
Endometrial Hyperplasia
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Intraductal, Noninfiltrating
2
Breast Neoplasms, Male
2
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Prostatic Neoplasms
1
Polycystic Ovary Syndrome
1
Peritoneal Neoplasms
1
Pathologic Complete Response
1
Obesity
1
Neoplasms by Site
1
Low-Grade Serous Ovarian Cancer
1
Low Grade Serous Ovarian Carcinoma
1
Low Grade Serous Ovarian Cancer
1
Locoregional Recurrence
1
Leiomyoma
1
Infertility, Female
1
Infertility
1
Interventions
pembrolizumab
38
Blood Specimen Collection
38
Bevacizumab
22
Surveys and Questionnaires
18
Standard of Care
18
Radiotherapy
17
Exercise
17
Carboplatin
17
Nivolumab
15
atezolizumab
14
Paclitaxel
14
Cisplatin
14
Drug Therapy
13
Fluorouracil
12
Cyclophosphamide
12
Cetuximab
11
Trastuzumab
10
Pemetrexed
10
Leucovorin
10
Docetaxel
10
Dexamethasone
10
Oxaliplatin
9
Biopsy
9
pertuzumab
8
olaparib
8
Temozolomide
8
Panitumumab
8
Observation
8
Irinotecan
8
abemaciclib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasms
×
Letrozole
×
Clear all
NCT05768139
2026-05-22
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled
NCT06979596
2026-05-13
OMAHA-015
Merck Sharp & Dohme LLC
Phase 2
Recruiting
250 enrolled
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled